Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
FDA hits Newron schizophrenia ph. 3 trial with hold after death
The patient's death was deemed unrelated to treatment, Newron said, and sudden death is more common in people with schizophrenia.
Darren Incorvaia
Apr 29, 2026 2:50pm
Tortugas comes out of shell with $106M, 4 ph. 2-stage neuro meds
Apr 21, 2026 10:41am
Alto halts work on PDE4 inhibitor after ph. 2 schizophrenia fail
Apr 2, 2026 7:17am
Boehringer cuts ties to Nxera's phase 2-ready schizophrenia drug
Dec 19, 2025 6:35am
Schizophrenia-minded Syremis takes off with $165M series A
Dec 18, 2025 12:59pm
MapLight goes public via $250M IPO to fund Cobenfy competitor
Oct 27, 2025 6:45am
